from Reuters: Health News https://reut.rs/2H4EyHc
Thursday, February 28, 2019
FDA flags concerns at Akorn's Amityville plant, shares slip
Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.
from Reuters: Health News https://reut.rs/2H4EyHc
from Reuters: Health News https://reut.rs/2H4EyHc
Subscribe to:
Post Comments (Atom)
-
(Reuters Health) - More than half of heart failure patients who visit the emergency room don't receive prompt follow-up care, and a Cana...
-
WEIGHT LOSS supplements could help overweight or obese patients with the diet plans. You could lose weight and avoid weight gain by adding...
-
A U.S. appeals court on Wednesday declined a request by Johnson & Johnson for an temporary restraining order blocking sales of generic v...
No comments:
Post a Comment